HK1256548A1 - 可用於基於免疫的肉毒桿菌毒素血清a型活性測定的細胞 - Google Patents

可用於基於免疫的肉毒桿菌毒素血清a型活性測定的細胞

Info

Publication number
HK1256548A1
HK1256548A1 HK18115618.0A HK18115618A HK1256548A1 HK 1256548 A1 HK1256548 A1 HK 1256548A1 HK 18115618 A HK18115618 A HK 18115618A HK 1256548 A1 HK1256548 A1 HK 1256548A1
Authority
HK
Hong Kong
Prior art keywords
immuno
botulinum toxin
activity assays
cells useful
toxin serotype
Prior art date
Application number
HK18115618.0A
Other languages
English (en)
Inventor
Birgitte P S Jacky
Joanne Wang
Hong Zhu
D Diane Hodges
Ester Fernandez-Salas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42288894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1256548(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1256548A1 publication Critical patent/HK1256548A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Rolling Contact Bearings (AREA)
HK18115618.0A 2009-03-13 2018-12-06 可用於基於免疫的肉毒桿菌毒素血清a型活性測定的細胞 HK1256548A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16019909P 2009-03-13 2009-03-13

Publications (1)

Publication Number Publication Date
HK1256548A1 true HK1256548A1 (zh) 2019-09-27

Family

ID=42288894

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115618.0A HK1256548A1 (zh) 2009-03-13 2018-12-06 可用於基於免疫的肉毒桿菌毒素血清a型活性測定的細胞

Country Status (25)

Country Link
US (19) US8361789B2 (zh)
EP (3) EP3858984A1 (zh)
JP (2) JP5717657B2 (zh)
KR (5) KR101898557B1 (zh)
CN (1) CN102439138B (zh)
AU (1) AU2010223910B2 (zh)
BR (1) BRPI1008940A2 (zh)
CA (1) CA2735242C (zh)
CL (1) CL2011002272A1 (zh)
CO (2) CO6440563A2 (zh)
CY (1) CY1120579T1 (zh)
DK (1) DK2406371T3 (zh)
ES (1) ES2689703T3 (zh)
HK (1) HK1256548A1 (zh)
HU (1) HUE038699T2 (zh)
IL (2) IL214794A (zh)
MX (1) MX2011009621A (zh)
MY (1) MY175803A (zh)
NZ (1) NZ594702A (zh)
PL (1) PL2406371T3 (zh)
PT (1) PT2406371T (zh)
RU (1) RU2011139364A (zh)
SG (1) SG174350A1 (zh)
SI (1) SI2406371T1 (zh)
WO (1) WO2010105234A1 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259928B1 (es) * 2005-04-08 2007-11-01 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica que comprende peptidos derivados de encefalinas para reducir y/o eliminar arrugas faciales.
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
EP3556770A1 (en) 2008-03-14 2019-10-23 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
JP5717657B2 (ja) 2009-03-13 2015-05-13 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 免疫系ボツリヌス毒素血清型ａ活性アッセイに有用な細胞
DE102010024898B4 (de) * 2010-06-24 2012-10-25 Merck Patent Gmbh Genexpressionsanalysen zur Charakterisierung und Identifizierung genotoxischer Verbindungen
US9217172B2 (en) * 2011-09-29 2015-12-22 Cellsnap, Llc Compositions and methods for toxigenicity testing
US10451621B2 (en) 2011-12-31 2019-10-22 Allergan, Inc. Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A
US20150153325A1 (en) * 2012-05-11 2015-06-04 Patrick McNutt Toxin detection using stem cell derived neurons
US9764010B2 (en) 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin
JP6300807B2 (ja) * 2012-10-16 2018-03-28 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 神経毒素ポリペプチドの生物学的活性の決定のための細胞試験系
KR102083371B1 (ko) 2012-11-21 2020-03-04 입센 바이오이노베이션 리미티드 단백질 가수분해 처리된 폴리펩티드의 제조방법
US20160289731A1 (en) 2012-11-21 2016-10-06 Merz Pharma Gmbh & Co, Kgaa Means and methods for determination of botulinum neurotoxin biological activity
WO2014100019A1 (en) 2012-12-18 2014-06-26 Allergan, Inc. Prophylactic treatment of herpes recurrence
JP6608357B2 (ja) 2013-06-28 2019-11-20 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法
US10408837B2 (en) * 2013-12-09 2019-09-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide substrates recognizable by type E botulinum neurotoxin
KR20150132581A (ko) * 2013-12-31 2015-11-25 재단법인 생물기술개발중심 항-vegf 항체 및 그것의 용도
US10921312B2 (en) 2014-02-19 2021-02-16 Merz Pharma Gmbh & Co. Kgaa Gangliosides for standardizing and increasing the sensitivity of cells to botulinum neurotoxins in in vitro test systems
US9943576B2 (en) 2014-04-30 2018-04-17 Allergan, Inc. Formulations of biologics for intravesical instillation
KR20170026624A (ko) 2014-07-07 2017-03-08 알러간, 인코포레이티드 조직 샘플에서 절단된 snap25를 검출하는 방법
KR20220048046A (ko) 2014-07-31 2022-04-19 알러간, 인코포레이티드 방광내 주입을 위한 생물학 제형
CN107003310B (zh) 2014-11-21 2019-07-19 莫茨药物股份两合公司 用于测定神经毒素多肽的生物活性的方法
JP6772138B2 (ja) 2014-12-19 2020-10-21 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞内のＢｏＮＴ／Ｅの生物学的活性を決定するための手段及び方法
TWI704156B (zh) 2015-03-04 2020-09-11 德商曼茲法瑪股份有限公司 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法
RU2019110875A (ru) 2016-09-13 2020-10-15 Аллерган, Инк. Небелковые композиции клостридиального токсина
SG11201912890SA (en) 2017-06-30 2020-01-30 Allergan Inc Dissolving film for delivery of a clostridial derivative
CA3105778A1 (en) 2018-07-05 2020-01-09 Allergan Pharmaceuticals International Limited Combination therapy with cgrp antagonists and clostridial derivatives
CA3112394A1 (en) 2018-09-13 2020-03-19 Allergan, Inc. Clostridial toxin - hyaluronic acid compositions
EP3825689A3 (en) * 2018-11-29 2021-09-15 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
US20210121541A1 (en) 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
WO2021005497A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
US20210130445A1 (en) 2019-07-05 2021-05-06 Allergan Pharmaceuticals International Limited CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders
EP3993825A1 (en) 2019-07-05 2022-05-11 Allergan, Inc. Methods for treating and for inhibiting progression of seizures
BR112023024599A2 (pt) * 2021-05-24 2024-02-20 Atgc Co Ltd Células sensíveis à toxina botulínica dentro das quais um gene específico foi inserido por um lentivírus
WO2022250442A1 (ko) * 2021-05-25 2022-12-01 휴젤㈜ 신경독소 역가 측정용 신규한 신경세포주
WO2024102345A1 (en) 2022-11-07 2024-05-16 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
CA2076386C (en) 1990-02-26 2003-04-22 David S. Hogness Identification and expression of insect steroid receptor dna sequence
CA2135644C (en) 1992-05-14 2009-01-27 Elisabetta Vegeto Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
BR9809138A (pt) 1997-05-21 2001-08-28 Trustees For The Leland Stanfo Conjugado e método para aumentar o transporte de um composto selecionado atravessando uma membrana biológica
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
EP1137664A2 (en) 1998-12-10 2001-10-04 Washington University Protein transduction system and methods of use thereof
CA2380457A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US6878543B1 (en) 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
US20030008813A1 (en) 1999-12-17 2003-01-09 Felgner Philip L. Intracellular protein delivery compositions and methods of use
GB9930519D0 (en) 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
CA2417454A1 (en) 2000-07-31 2002-02-07 Active Motif Peptide-mediated delivery of molecules into cells
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
DK1718756T3 (da) 2004-02-24 2012-02-27 Allergan Inc Botulinumtoksinscreeningassays
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US20070258992A1 (en) 2004-10-06 2007-11-08 Atassi M Zouhair Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
WO2006099590A2 (en) 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP2264458A1 (en) * 2005-04-05 2010-12-22 Allergan, Inc. Clostridial toxin activity assays
CA2604039C (en) 2005-04-05 2014-09-16 Allergan, Inc. Lipophilic dye-based fret assays for clostridial toxin activity
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
EP2038298A2 (en) 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
EP3556770A1 (en) * 2008-03-14 2019-10-23 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
JP5717657B2 (ja) * 2009-03-13 2015-05-13 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 免疫系ボツリヌス毒素血清型ａ活性アッセイに有用な細胞
AU2010223912B2 (en) 2009-03-13 2015-09-24 Allergan, Inc. Immuno-based retargeted endopeptidase activity assays

Also Published As

Publication number Publication date
US20120208272A1 (en) 2012-08-16
US20120156774A1 (en) 2012-06-21
EP3330372A1 (en) 2018-06-06
US8455213B2 (en) 2013-06-04
US8455247B2 (en) 2013-06-04
US20120149105A1 (en) 2012-06-14
CO6440562A2 (es) 2012-05-15
US20120149104A1 (en) 2012-06-14
US20120156776A1 (en) 2012-06-21
KR20200146046A (ko) 2020-12-31
US20120156769A1 (en) 2012-06-21
CO6440563A2 (es) 2012-05-15
WO2010105234A1 (en) 2010-09-16
US8455248B2 (en) 2013-06-04
IL214794A0 (en) 2011-11-30
ES2689703T3 (es) 2018-11-15
CA2735242C (en) 2017-01-24
CL2011002272A1 (es) 2012-03-23
US20230323290A1 (en) 2023-10-12
KR101762970B1 (ko) 2017-07-31
US20130236963A1 (en) 2013-09-12
SI2406371T1 (sl) 2018-10-30
PT2406371T (pt) 2018-10-18
KR102017327B1 (ko) 2019-09-03
US8361789B2 (en) 2013-01-29
US20210163887A1 (en) 2021-06-03
MX2011009621A (es) 2011-12-16
US20120149103A1 (en) 2012-06-14
JP2012520083A (ja) 2012-09-06
KR20190104231A (ko) 2019-09-06
US8663982B2 (en) 2014-03-04
MY175803A (en) 2020-07-09
IL240785A (en) 2016-06-30
PL2406371T3 (pl) 2018-11-30
US9625447B2 (en) 2017-04-18
HUE038699T2 (hu) 2018-11-28
US8501469B2 (en) 2013-08-06
NZ594702A (en) 2013-05-31
US8476069B2 (en) 2013-07-02
CN102439138A (zh) 2012-05-02
CA2735242A1 (en) 2010-09-16
JP5717657B2 (ja) 2015-05-13
JP6105645B2 (ja) 2017-03-29
US8603812B2 (en) 2013-12-10
BRPI1008940A2 (pt) 2020-10-27
US8603813B2 (en) 2013-12-10
US20120214229A1 (en) 2012-08-23
US20120214231A1 (en) 2012-08-23
EP3858984A1 (en) 2021-08-04
US20120156775A1 (en) 2012-06-21
IL214794A (en) 2015-09-24
JP2015077153A (ja) 2015-04-23
US20120164728A1 (en) 2012-06-28
EP2406371B1 (en) 2018-05-09
CY1120579T1 (el) 2019-07-10
US8691566B1 (en) 2014-04-08
KR20120001757A (ko) 2012-01-04
IL240785A0 (en) 2015-10-29
RU2011139364A (ru) 2013-04-20
US8476068B2 (en) 2013-07-02
US20170218334A1 (en) 2017-08-03
US20140093957A1 (en) 2014-04-03
US20100233802A1 (en) 2010-09-16
KR20170086699A (ko) 2017-07-26
AU2010223910B2 (en) 2015-03-12
US20120149106A1 (en) 2012-06-14
CN102439138B (zh) 2018-03-30
AU2010223910A1 (en) 2011-09-15
US8663983B2 (en) 2014-03-04
US20120208271A1 (en) 2012-08-16
DK2406371T3 (en) 2018-08-13
US8507271B2 (en) 2013-08-13
KR101898557B1 (ko) 2018-09-14
SG174350A1 (en) 2011-10-28
KR20180102695A (ko) 2018-09-17
EP2406371A1 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
HK1256548A1 (zh) 可用於基於免疫的肉毒桿菌毒素血清a型活性測定的細胞
HK1225746A1 (zh) 基於免疫的血清型a肉毒桿菌毒素活性測定
HK1169855A1 (zh) 基於免疫的重靶向內肽酶活性測定
ZA201206842B (en) A novel ethanologenic clostridium species, clostridium coskatii
EP2516669A4 (en) ANALYZES OF ENZYMES ON A DIFFUSER WITH DROPLETS
EP2451476A4 (en) BIOTRAITEMENT BASED ON CELLS
EP2473948A4 (en) AUTOMATED COMPACT CELL COUNTER
IL216168A0 (en) Smart packing for detecting microorganisms
EP2324350A4 (en) REFERENCE CHECKS FOR CELLAR ANALYSIS
GB2467852B (en) Automated structural interpretation
HK1170503A1 (zh) β細胞標記抗體
EP2271739A4 (en) CELL CULTURE PRODUCT
HK1173634A1 (zh) 梭菌神經毒素的定量檢測方法
EP2712423A4 (en) ANALYZES FOR DETECTING ENZYMATIC ACTIVITY
ZA200905287B (en) A medium for a cell culture
BRPI1009861A2 (pt) célula de bateria, disposição de bateria e método para a sua produção
GB0806910D0 (en) A flow-through-cell for measuring biomass
GB0813439D0 (en) Diagnosis using a T cell assay
GB0909355D0 (en) Improved cell based assay method